TherapeuticsMD (TXMD) Tops Q3 EPS by 4c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.07), $0.04 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.22 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• zSpace, Inc. (ZSPC) Reports Q2 results